Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Thursday, 24 August 2023, 09:11 HKT/SGT
Share:
    

Source: NEC Corporation
BostonGene, NEC and JIP Form Joint Venture in Japan
AI-based molecular and immune profiling and bioanalytics streamline drug development and advance precision medicine for cancer patients

TOKYO, Aug 24, 2023 - (JCN Newswire) - BostonGene, a leading provider of AI-based molecular and immune profiling solutions, NEC Corporation (TSE: 6701), a leader in IT, network and AI technologies, and Japan Industrial Partners, a leading Tokyo-based private equity firm, today announced the formation of BostonGene Japan Inc., a Tokyo-based joint venture aimed at advancing personalized medicine and dramatically improving patient outcomes. The new company will utilize BostonGene's high-complexity molecular technology and advanced biocomputational algorithms, including BostonGene Tumor Portrait tests, to accelerate the development and validation of novel precision medicine approaches.

BostonGene's AI-powered cloud-based solutions, bioinformatics capabilities, analytical tools, and advanced next-generation molecular and immune profiling provide a comprehensive view of a cancer patient at a molecular level and identify actionable targets to make evidence-based treatment decisions. In addition, BostonGene uses its solution platform to provide a broad range of services for biopharma customers, including biomarker discovery, clinical trial testing, assay design and development, and companion diagnostics.

Data show that one in four deaths in Japan is caused by cancer, with recent numbers indicating that mortality is steadily rising(*). By equipping cancer care centers with BostonGene solutions, a greater number of patients will be able to benefit from genomic testing and personalized treatments. Furthermore, by utilizing BostonGene industry solutions, Japanese researchers and biopharma companies will benefit from biomarker-driven therapy development.

"We look forward to bringing BostonGene solutions to the Japanese market. Our deep molecular and immune profiling and biocomputational power drastically improve patient outcomes and therapy development. Already widely adopted in the United States, we firmly believe that our solutions will significantly improve the standard of cancer care in Japan by enabling personalized treatments and improving therapy development," said Andrew Feinberg, President and CEO, BostonGene.

"NEC is actively promoting the growth of its healthcare and life science business, centered on its hospital DX business, which has a strong customer base. By collaborating with NEC's healthcare solutions, which utilize powerful AI/digital technologies, we expect BostonGene's solutions to transform cancer care in Japan and aid Japanese pharmaceutical companies in developing the most effective therapies," said Takayuki Morita, President and CEO, NEC Corporation.

"JIP is delighted to be able to support NEC's efforts to create a healthcare and life science business by utilizing the technology of BostonGene," said Hidemi Moue, CEO, Japan Industrial Partners.

Note:
(*) Foundation for Promotion of Cancer Research, "CANCER STATISTICS IN JAPAN ─ 2023," p40 (p42 of the pdf). Retrieved from (https://ganjoho.jp/public/qa_links/report/statistics/pdf/cancer_statistics_2023.pdf)

About BostonGene Corporation

BostonGene's mission is to power healthcare's transition to personalized medicine using our AI-based molecular and immune profiling to improve the standard of care, accelerate research, and reduce the overall cost of cancer care. BostonGene's tests reveal key drivers of each tumor, including immune microenvironment properties, actionable mutations, biomarkers of response to diverse therapies, and recommended therapies. Through these comprehensive analyses, BostonGene's tests generate a personalized roadmap for therapeutic decision-making for each cancer patient. For more information, visit BostonGene at www.BostonGene.com.

About NEC Corporation

NEC Corporation has established itself as a leader in the integration of IT and network technologies while promoting the brand statement of "Orchestrating a brighter world." NEC enables businesses and communities to adapt to rapid changes taking place in both society and the market as it provides for the social values of safety, security, fairness and efficiency to promote a more sustainable world where everyone has the chance to reach their full potential. For more information, visit NEC at www.nec.com.

About Japan Industrial Partners, Inc.

Japan Industrial Partners (JIP) is a private equity firm based in Tokyo, Japan, specialized in corporate carve-out investments in Japan. JIP provides funds and solutions to businesses with significant room for improvement and growth opportunities.


Topic: Press release summary
Source: NEC Corporation

Sectors: Cloud & Enterprise, Artificial Intel [AI], MedTech
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.


NEC Corporation Links

http://www.nec.com

https://www.facebook.com/nec.global/

https://twitter.com/NEC_corp

https://www.youtube.com/user/NECglobalOfficial

https://www.linkedin.com/company/nec/

NEC Corporation
Apr 24, 2024 12:25 HKT/SGT
NEC Develops High-speed Generative AI Large Language Models (LLM) with World-class Performance
Apr 22, 2024 14:09 HKT/SGT
NEC Strengthens Commitment to Space Industry with Investment in Seraphim Space Venture Fund II
Apr 11, 2024 14:10 HKT/SGT
DOCOMO, NTT, NEC and Fujitsu Develop Top-level Sub-terahertz 6G Device Capable of Ultra-high-speed 100 Gbps Transmission
Apr 10, 2024 12:36 HKT/SGT
Transgene and NEC Present First Clinical Benefits of Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at AACR 2024
Apr 8, 2024 12:45 HKT/SGT
NEC white paper proposes comprehensive process workflow for the application of AI-driven personalized cancer vaccines
Mar 25, 2024 09:08 HKT/SGT
NEC develops marketing strategy planning & effectiveness simulation technology using generative AI
Mar 22, 2024 07:38 HKT/SGT
NEC and NTT successfully conduct first-of-its-kind long-distance transmission experiment over 7,000km using 12-core optical fiber
Mar 21, 2024 09:02 HKT/SGT
NEC and Tokyo Medical and Dental University use AI to assist self-care for chronic lower back pain
Mar 20, 2024 14:30 HKT/SGT
NEC and Skyloom to Pioneer 100 Gbps Space Optical Communications, Transforming Global Internet Connectivity
Mar 7, 2024 10:24 HKT/SGT
NEC named to list of Top 100 Global Innovators by Clarivate for 13th consecutive year
More news >>
 News Alerts
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: